CLINICAL TRIALS PROFILE FOR FLUPHENAZINE DECANOATE
✉ Email this page to a colleague
All Clinical Trials for fluphenazine decanoate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00014001 ↗ | CATIE- Schizophrenia Trial | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2000-12-01 | The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate. |
| NCT00356200 ↗ | Fluphenazine Decanoate for Psoriasis | Terminated | Immune Control | Phase 2 | 2006-07-01 | We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study. |
| NCT00356200 ↗ | Fluphenazine Decanoate for Psoriasis | Terminated | Tufts Medical Center | Phase 2 | 2006-07-01 | We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for fluphenazine decanoate
Condition Name
Clinical Trial Locations for fluphenazine decanoate
Trials by Country
Clinical Trial Progress for fluphenazine decanoate
Clinical Trial Phase
Clinical Trial Sponsors for fluphenazine decanoate
Sponsor Name
